DOCSLIB.ORG

Summarised Financial Statements 2012

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Summarised Financial Statements 2012 Summarised Financial Statements 2012 Contents Chairman’s Statement 02 02 Summary Trustee’s Report 04 04 Vision and Objects, Mission, Focus Areas 04 and Challenges Financial Review 06 Extracts from the Review of Investment Activities 08 Independent Auditors’ Report 10 10 Consolidated Statement of Financial Activities 11 Consolidated Balance Sheet 12 Consolidated Cash Flow Statement 13 Grants Awarded 14 Reference and Administrative Details 16 Chairman’s Statement Sustained investment in research can bring real benefits or Medicine which was shared by a dozens of genomes every day. Their former Governor of the Trust, work is driving the first wave of Professor Sir John Gurdon. His work stratified medicine, improving cancer showed that mature cells had the therapy for patients by examining the potential to be reprogrammed into genetics of individual tumours, and stem cells. Subsequent decades of revealing the genetic basis of the way investment in stem cell research have specific cancers respond to different brought us ever closer to realising the drugs. promise of stem cell therapies. At the same time, ever-improving We saw again this year how sustained technology is giving us an advantage investment in research can bring real against infectious diseases. A study benefits. Genetics has been one of the published this summer demonstrated Trust’s most focused areas of funding how modern genome sequencing Summary of Chairman’s since the mid-1990s. First, we sought could track methicillin-resistant Statement to decode the human genome; then Staphylococcus aureus (MRSA). we had to find ways to apply that Retrospective analysis of samples • We committed £701 million in grant knowledge. I think we are at a stage from a real outbreak of MRSA in a funding and direct charitable now when we can stop talking about hospital showed that the outbreak activities this year, mostly in grants genetics improving health in the could have been identified and to scientists working in medical future – it is improving health today. stopped sooner with the new research, and most of them in Looking forward, the Trust is funding technology. This approach could help the UK. a clinical trial of a gene therapy for to control outbreaks of hospital- choroideraemia, a rare genetic acquired infections more effectively • Central to much of the genetics disorder that slowly causes people to than existing laboratory techniques. research we fund is the Wellcome lose their eyesight. The therapy uses a Trust Sanger Institute. We have benign virus to deliver a healthy copy Changing world invested more than £1 billion there of the defective gene into patients’ Britain was the workshop of the world over the last 18 years. eyes. The trial began in October 2011 150 years ago. Today, we have a new and, this time next year, we should role as one of the leading ‘knowledge • The future of science really does know whether it has been successful shops’ in the world. Through depend on the quality of science in halting loss of sight in the first 12 partnerships with other funders, education today. patients. universities, businesses, charities and government agencies, we can • Our investment returns drive our Central to much of the genetics facilitate creative interactions ability to make charitable research we fund is the Wellcome between researchers in all sectors. commitments. In 2011/12, we Trust Sanger Institute. We have The Wellcome Trust continues to returned £1.6 billion, bringing our invested more than £1 billion there invest substantially in the UK’s investment return over ten years to over the last 18 years. The Sanger universities, but we are also ensuring 145% and over twenty years to 411%. Institute was at the heart of the that their scientific discoveries can be Human Genome Project, providing used to improve healthcare. one third of the sequence decoded The Wellcome Trust committed £701 over ten years; today, it continues to For example, together with million in grant funding and direct lead the world in this field. With data GlaxoSmithKline and the UK charitable activities this year, mostly capacity currently at 16 million government, the Trust funds in grants to scientists working in gigabytes and a staff of 850, Stevenage Bioscience Catalyst, where medical research, and most of them in collaborating with the European academic and industry scientists work the UK. I was thrilled this October Bioinformatics Institute on the same side by side in an ethos of ‘open when the UK’s strength in basic site and with thousands of other innovation’. The first tenants moved biomedical research was recognised scientists around the world, the in this February. By working on the by the 2012 Nobel Prize in Physiology Sanger Institute now sequences same site, researchers from different 2 | Summarised Annual Report And Financial Statements 2012 fields and sectors will be able to share assets, designed to be held for many intention was always that science expertise and exchange ideas. This years or even decades. Over the past could also be understood and used by should lead to new projects and the five years, the main illiquid the public. We had a golden faster and more effective translation investments have delivered returns opportunity to bring science to the of research into patient benefit. about 25% higher than those from public as the London 2012 Olympic public equities. and Paralympic Games entertained Investments and inspired the country. Our I am very pleased at the start made by Our macro-economic prognosis is not contribution to the Olympic spirit Syncona, our new investment positive as fiscal austerity and debt was In The Zone, providing over company set up this year specifically deleveraging continues. However, we 30,000 UK schools with kits full of to invest in the health and think that companies, focused on the ideas for exciting classroom biotechnology sectors. By investing in opportunities created by ageing experiments focusing on the science exciting opportunities in the populations, the shift to disruptive of the body in motion. These will help translation of research into new knowledge-based industries, new teachers nurture a love of science in treatments and patient care Faster Growing Markets in Africa, their students for years to come. technologies, we expect it will make Asia and Latin America and resource significant returns for the Trust in the scarcity, with a global long-term The popularity of science in schools longer term. Syncona has already horizon and patient investors, will be continues to rise again, countering a made its first investment and looks set best placed in this environment. decline in the numbers of students to be a valuable catalyst to create taking science and maths A Levels value through new healthcare A strong legacy through most of the 1990s. The rise companies at an early stage of Sir Mark Walport will be stepping has coincided with the Wellcome development. down as Director of the Wellcome Trust’s support for the National Trust at the end of March 2013. I’m Science Learning Centre in York, Our investment returns drive our sure there will be many opportunities which provides continuing ability to make charitable to thank him and wish him well in his professional development training to commitments. In 2011/12, we returned new role as the UK’s Chief Scientific teachers so that they can keep up with £1.6 billion, bringing our investment Adviser. For now, I will just say that the latest developments in science and return over ten years to 145% and over his contribution over the last ten how best to teach it. Alongside this, in twenty years to 411%. These returns years has been enormous. In the 2008 we launched Project ENTHUSE, exceeded those from public equities meantime, I would like to thank Peter a £27 million partnership between the but were achieved with considerably Davies, Roderick Kent and Professor Trust, the UK government and lower reported volatility. Our net Chris Fairburn, who all stepped down industry, to provide bursaries that portfolio value is £14.5 billion. from the Board of Governors this enable teachers to cover the full costs Charitable cash payments in the year year, for their immeasurable of attending these courses. Our of £643 million are twice the level at contributions to the Trust’s activities. 7000th bursary was awarded this year the turn of the century and are 35% and the government has renewed its higher than in the year 2006/07 In their place, we welcomed three new commitment to the scheme for a before the global financial crisis; Governors. Professor Mike Ferguson further five years. steady growth in each subsequent is a researcher in parasitology at the year has provided useful stability to University of Dundee, with a The future of science really does UK medical research as other funding particular interest in translational depend on the quality of science sources have come under pressure. research; he is also the Dean of education today. By supporting Research for the College of Life science teachers, we are fostering the Our investment team, led by Danny Sciences at Dundee. Alan Brown has next generation of researchers and a Truell, has evolved our portfolio in a enjoyed a career of nearly 40 years in society that will cherish and support number of ways. The portfolio has investment management, most their work. It is an integral part of our been globalised such that net UK and recently as Chief Investment Officer long-term vision of funding the other European assets now account of Schroders. And Damon Buffini brightest minds to achieve for only 13% of the portfolio compared is a founding partner of one of extraordinary improvements in with 48% in 2006, providing some Europe’s most successful private health.
Load more

Recommended publications
  • Wellcome Trust Annual Report and Financial Statements 2017 Contents
    Annual Report and Financial Statements 2017 2 Wellcome Trust Annual Report and Financial Statements 2017 Contents Report from the Chair and the Director 5 Trustee’s Report 8 What we do 8 Review of Charitable Activities 9 Review of Investment Activities 18 Financial Review 29 Structure and Governance 34 Risk Management 37 Remuneration Report 40 Audit Committee Report 43 Independent Auditor’s Report 45 Financial Statements 58 Consolidated Statement of Financial Activities 58 Consolidated Balance Sheet 59 Statement of Financial Activities of the Trust 60 Balance Sheet of the Trust 61 Consolidated Cash Flow Statement 62 Notes to the Financial Statements 63 Reference and Administrative Details 117 3 Wellcome Trust Annual Report and Financial Statements 2017 “ At Wellcome, we believe in the power of ideas to improve health” Jeremy Farrar Director 4 Wellcome Trust Annual Report and Financial Statements 2017 Report from the Chair and the Director “Our core approach is funding people to explore great ideas, at every step of the way from discovery to impact” At Wellcome, we believe in the power of ideas to improve cause of maternal mortality in the world. It also includes health. Funded from our independent investment portfolio, supporting research in the humanities and social sciences, we support thousands of scientists and researchers in more such as a project which this year published ethical guidelines than 70 countries, as well as innovators, educators and artists. for involving pregnant women in Zika vaccine research. Together, we take on big problems, fuel imaginations and spark And resources like the Human Induced Pluripotent Stem Cell debate, working always to achieve better health for everyone.
    [Show full text]
  • ANNUAL REVIEW 1 October 2005–30 September
    WELLCOME TRUST ANNUAL REVIEW 1 October 2005–30 September 2006 ANNUAL REVIEW 2006 The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. It funds innovative biomedical research, in the UK and internationally, spending around £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk THE WELLCOME TRUST The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. 123 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell 4 Advancing knowledge Chairman 16 Using knowledge Martin Bobrow Deputy Chairman 24 Engaging society Adrian Bird 30 Developing people Leszek Borysiewicz 36 Facilitating research Patricia Hodgson 40 Developing our organisation Richard Hynes 41 Wellcome Trust 2005/06 Ronald Plasterk 42 Financial summary 2005/06 Alastair Ross Goobey 44 Funding developments 2005/06 Peter Smith 46 Streams funding 2005/06 Jean Thomas 48 Technology Transfer Edward Walker-Arnott 49 Wellcome Trust Genome Campus As at January 2007 50 Public Engagement 51 Library and information resources 52 Advisory committees Images 1 Surface of the gut. 3 Zebrafish. 5 Cells in a developing This Annual Review covers the 2 Young children in 4 A scene from Y fruit fly. Wellcome Trust’s financial year, from Kenya. Touring’s Every Breath. 6 Data management at the Sanger Institute. 1 October 2005 to 30 September 2006. CONTENTS 1 45 6 EXECUTIVE BOARD MAKING A DIFFERENCE Developing people: To foster a Mark Walport The Wellcome Trust’s mission is research community and individual Director to foster and promote research with researchers who can contribute to the advancement and use of knowledge Ted Bianco the aim of improving human and Director of Technology Transfer animal health.
    [Show full text]
  • A DNA Database in the NHS: Your Freedom up for Sale?
    A DNA database in the NHS: Your freedom up for sale? May 2013 In April 2013, the Caldicott Committee, including Government Chief Scientist Sir Mark Walport, proposed new rules for data-sharing which would allow the Government to build a DNA database of the whole population of England in the NHS by stealth.1 The plan is to make NHS medical records and people’s genetic information available to commercial companies and to use public-private partnerships to build a system where all private information about every citizen is also accessible to the police, social workers, security services and Government. The Wellcome Trust, which was involved in the Human Genome Project and was led by Walport for ten years, has produced a plan which involves including a variant file, containing the whole genome of every person minus the reference genome, as an attachment to every medical record in the NHS in England.2 This data would be made available to ‘researchers’ (including commercial companies) for data-mining in the cloud and personalised risk assessments would be returned to individuals. The aim is to transform the NHS in line with proposals developed more than a decade ago by former GlaxoSmithKline Chairman Sir Richard Sykes. This is expected to massively expand the market for medicines, medical tests and other products, such as supplements and cholesterol-lowering margarines, by allowing products to be marketed to individuals based on personal risk assessments, created using statistical analysis of genetic data, medical records and other health information. The proposal to build a DNA database in the NHS was endorsed by the Human Genomics Strategy Group in 20123,4 and the Government (led by Prime Minister David Cameron) has quietly adopted this recommendation without telling members of the public.
    [Show full text]
  • Vol 9 No 1 Spring
    A PUBLICATION OF THE AMERICAN SOCIETY FOR MATRIX BIOLOGY SPRING 2010, VOLUME 9, NO. 1 President’s Letter Expanding the Society’s Value to You and Your Role in the Society Since its inception in 2001, the principal function of the ASMB has been to organize the OFFICERS biennial meeting. The value of this meeting to our members cannot be understated. The ASMB meeting has emerged as the matrix-centric President: meeting in North America, and it provides an William Parks (2010) open venue for students, postdocs, fellows, and junior faculty to present their work and to inter- act with established investigators. Speaking for Vice Pres/President Elect myself, I very much look forward to the ASMB Jean Schwarzbauer (2010) meeting, not only because I get to see many Bill Parks friends, but also to hear a lot of incredibly good science. This year’s meeting will be no excep- Past President: tion and promises to be truly outstanding. I applaud Jean Schwarzbauer and the Renato Iozzo (2010) rest of the Program Committee for putting together an exciting meeting loaded with interesting topics and great speakers (please check out the program here). By organizing the meeting, ASMB provides value to you, the membership, but I Secretary/Treasurer think we–the Society–should always be looking to do more; that is, to provide more Joanne Murphy-Ullrich (2011) bang for your dues buck. For this year’s meeting, we have expanded the Travel Awards that will be given to trainees in recognition of outstanding research, and we recently established merit-based Minority Scholarships that will be awarded to eli- Council Members gible students and postdocs.
    [Show full text]
  • SAC 2014 Celebration of Science Book
    Fostering Innovation at MGH Poster Session Abstracts 67th Annual Meeting of the MGH Scientific Advisory Committee Celebration of Science The MGH Research Institute: Meeting the Challenges that Lie Ahead April 2 & 3, 2014 Simches Auditorium 185 Cambridge Street, 3rd Floor Management Management ECOR Administrative Offices | 50 Staniford Street, 10th Floor | Boston, MA 02114 | [email protected] Fostering Mainstay Mainstay Innovation of MGH of MGH at MGH Management Innovation Management Innovation Welcome elcome to the 67th Annual Meeting of the MGH Scientific Advisory Committee (SAC) on April 2nd and 3rd, 2014. Dr. Richard Lifton has graciously agreed to W chair our SAC meeting again this year. As in past years, we will begin our two-day SAC meeting with a Celebration of Science at MGH. Our poster session begins at 11:00 am on Wednesday, April 2, followed by an afternoon Research Symposium from 2:00 pm to 5:00 pm. The outstanding MGH researchers who will be presenting their work in our Symposium this year are the 2014 Howard Goodman Award recipient Filip Swirski, PhD and the 2014 Martin Basic and Clinical Research Prize recipients, Jayaraj Rajagopal, MD, and Stephanie Seminara, MD. We are honored to have as our keynote speaker, Richard O. Hynes, PhD, from MIT. We will close the first day with a Reception for invited guests at the Russell Museum. On Thursday, April 3, Dr. Kingston will open the SAC meeting with an ECOR Report. After this report, Anne Klibanski, MD, Partners Chief Academic Officer, will give a presentation on the Integration of MGH Research to the Partners Enterprise.
    [Show full text]
  • Cambridge University Reporter, Thursday, 1 December 2011
    CAMBRIDGE UNIVERSITY REPORTER S PECIAL N O 4 T HUR S D AY 1 D ECEMBER 2011 VOL CXLII MEMBERS OF UNIVERSITY BODIES REPRESENTATIVES OF THE UNIVERSITY PUBLISHED BY AUTHORITY MEMBERS OF UNIVERSITY BODIES REPRESENTATIVES OF THE UNIVERSITY P ART II. M EMBER S OF U N I V ER S I T Y B ODIE S Faculty Boards and Degree Committees 18 Committees 25 Nominating and appointing bodies: Trustees, Managers, Awarders, of Funds, abbreviations 1 Scholarships, Studentships, Prizes, etc. 31 Septemviri, Court of Discipline 1 Representatives of the Colleges and Approved University Tribunal, Summary Court 1 Foundations for Election of Members of Council, Audit Committee, Finance Committee 2 the Finance Committee 47 General Board of the Faculties 2 Other Committees of the Central Bodies 2 Boards of Electors to Professorships 5 P ART III. R EPRE S E ntAT I V E S OF T HE Advisory Committees for elections to Professorships 6 U N I V ER S I T Y Boards of Electors to offices other than Professorships 7 Syndicates 7 1. Representative Governors, etc. 48 Boards 9 2. Representative Trustees 50 Councils of the Schools 11 3. Cambridge Foundation: Trustees 50 Appointments Committees 12 4. Cambridge Enterprise Ltd: Board of Directors 50 NOTICE BY THE EDITOR This issue of the Officers Number comprises a revised version of Part II and Part III and includes data received up to 14 November 2011. Part I (University Officers) will be published separately. The next issue (Parts II and III) will be published in the Lent Term 2012. NOTES (1) The mention of a year after a name or a set of names in Part II means, unless it is otherwise specified, that retirement from membership is due on 31 December of that year.
    [Show full text]
  • Hhmi Bulletin 3 4 Hhmi Club
    HHMI BULLETIN 4000 Jones Bridge Road • Chevy Chase, Maryland 20815-6789 Howard Hughes Medical Institute www.hhmi.org One Lump or Two? in this issue Once again, those fast-growing yeast find a way to turn a The Silicon Marvel long-held theory on its head. This time, it’s about prions, • Prions for Good which aren’t as universally nasty as once suspected. Some may actually help organisms evolve. The yeast colony shown here www.hhmi.org A Kaleidoscopic View contains a protein in its prion form. Because the prion, known as PSI+, is self-replicating and forms fibrous amyloids, the yeast look lumpy and bumpy—strikingly different from normally smooth yeast. Susan Lindquist’s group has found 19 yeast proteins that can switch back and forth between a normal and a prion version. The prions are thought to help the yeast adapt to changing conditions (see “A Silver Lining,” page 22). LIGHT MOVES v ol. 23 Heather True / Lindquist lab /no. 02 O b s e r v a t i O n s 16 Secret Agent MAn Skin cells do more than just cover our bodies. As a neurology resident, Stanley Prusiner saw Creutzfeldt–Jakob agent began to emerge. These data established, for the first time, that Keratinocytes, for example, anchor immune cells disease kill a patient in a matter of months. Researchers knew the rare a particular macromolecule was required for infectivity and that this within the epidermis, move and proliferate during neurodegenerative disease and scrapie, a similar disease in sheep, macromolecule was a protein …. wound healing, and even secrete inhibitory molecules were infectious but not as a result of a typical virus.
    [Show full text]
  • February 7, 2007 (Download PDF)
    Volume 51 – Number 16 Wednesday – February 7, 2007 TechTalk S ERVING T HE M I T C OMMUNITY Reactivated gene shrinks tumors, MIT study finds Anne Trafton cancer treatments,” said David Kirsch of known whether such activity would actu- properly, it activates DNA repair mecha- News Office MIT’s Center for Cancer Research and ally reverse tumor growth in primary nisms and prevents cells with damaged Harvard Medical School, one of the lead tumors. DNA from dividing. If DNA damage is co-authors of the paper. The new MIT study shows that re-acti- irreparable, p53 induces the cell to destroy Many cancers arise due to defects in The study appeared in the Jan. 25 vating p53 in mouse tumors dramatically itself by undergoing apoptosis, or pro- genes that normally suppress tumor issue of Nature. It was conducted in the reduces the size of the tumors, in some grammed cell death. growth. Now, for the first time, MIT laboratory of Tyler Jacks, director of the cases by 100 percent. When p53 is turned off by mutation researchers have shown that re-activat- Center for Cancer Research, the David H. “This study provides critical genetic or deletion, cells are much more likely ing one of those genes in mice can cause Koch Professor of Biology and a Howard evidence that continuous repression of a to become cancerous, because they will tumors to shrink or disappear. Hughes Medical Institute investigator. tumor suppressor gene is required for a divide uncontrollably even when DNA is The study offers evidence that the P53 has long been known to play a tumor to survive,” said Andrea Ventura, an damaged.
    [Show full text]
  • 2019: the Year in Experimental Medicine Why Submit to Jem?
    2019: THE YEAR IN EXPERIMENTAL MEDICINE WHY SUBMIT TO JEM? FORMAT NEUTRAL You may submit your papers in ANY format. 92% OF INVITED REVISIONS ARE ACCEPTED TRANSFER POLICY We welcome submissions that include reviewer comments from another journal. You may also request manuscript transfer between Rockefeller University Press journals, and we can confidentially send reviewer reports and identities to another journal beyond RUP. INITIAL DECISION IN 6 DAYS FAIR AND FAST We limit rounds of revision, and we strive to provide clear, detailed decisions that illustrate what is expected in the revisions. Articles appear online one to two days after author proofs are returned. TIME IN PEER REVIEW 38 DAYS OPEN ACCESS OPTIONS Our options include Immediate Open Access (CC-BY) and open access six months after publication (CC-BY-NC-SA). *Median 2019 An Editorial Process Guided by Your Community At JEM, all editorial decisions on research manuscripts are made through collaborative consultation between professional scientific editors and the academic editorial board. Submission or transfer Academic and scientific If appropriate, sent Academic and scientific Informed decisions editors review to Peer Review editors review comments sent to authors Revised manuscript Academic and scientific 92% of invited Published online Circulated via alerts and submission and rereview editors review revisions accepted* 1-2 days after author social media to readers proofs returned around the world 2019: THE YEAR IN EXPERIMENTAL MEDICINE t the beginning of 2020, the start of a new decade, the Journal of Experimental Medicine (JEM) is proud to present our annual Year in Experimental Medicine collection to highlight some of the articles that were of greatest interest to our readers last year.
    [Show full text]
  • Wellcome Trust Finance Plc (Incorporated in England and Wales Under the Companies Act 1985 with Registered Number 5857955) £275,000,000 4.75 Per Cent
    Wellcome Trust Finance plc (incorporated in England and Wales under the Companies Act 1985 with registered number 5857955) £275,000,000 4.75 per cent. Guaranteed Bonds due 2021 guaranteed (as described herein) by Wellcome Trust (a charity registered under the Charities Act 1993 with registered number 210183) Issue Price 98.902 per cent The £275,000,000 4.75 per cent. Guaranteed Bonds due 2021 (the “Bonds”) will be issued by Wellcome Trust Finance plc (the “Issuer”). The payment of all amounts due in respect of the Bonds will be unconditionally and irrevocably guaranteed pursuant to the terms of a guarantee (the “Guarantee”) given by The Wellcome Trust Limited (in its capacity as trustee of the Wellcome Trust). Interest on the Bonds is payable annually in arrear on 28 May in each year. Payments on the Bonds will be made without withholding or deduction for or on account of taxes of the United Kingdom to the extent described under “Terms and Conditions of the Bonds – Taxation”. The Bonds will mature on 28 May 2021 but may be redeemed before that date at the option of the Issuer in whole but not in part at any time at a redemption price which is equal to the higher of (i) their principal amount and (ii) a price calculated by reference to the yield on the relevant United Kingdom government stock, plus 0.10 per cent., in each case, together with accrued interest. See “Terms and Conditions of the Bonds – Redemption and Purchase”. The Bonds are also subject to redemption in whole but not in part, at their principal amount, together with accrued interest, at the option of the Issuer at any time in the event of certain changes affecting taxes of the United Kingdom.
    [Show full text]
  • MSU Commencement Ceremonies Fall 2020
    COMMENCEMENT CEREMONIES FALL 2020 “Go forth with Spartan pride and confdence, and never lose the love for learning and the drive to make a diference that brought you to MSU.” Samuel L. Stanley Jr., M.D. President Michigan State University Photo above: an MSU entrance marker of brick and limestone, displaying our proud history as the nation’s pioneer land-grant university. On this—and other markers—is a band of alternating samara and acorns derived from maple and oak trees commonly found on campus. This pattern is repeated on the University Mace (see page 10). Inside Cover: Pattern of alternating samara and acorns. Michigan State University photos provided by University Communications. ENVIRONMENTAL TABLE OF CONTENTS STEWARDSHIP Mock Diplomas and the COMMENCEMENT Commencement Program Booklet 3 Virtual Commencement Ceremonies Commencement mock diplomas, 4 The Michigan State University Board of Trustees which are presented to degree 5 Michigan State University Mission Statement candidates at their commencement 6–8 Congratulatory Letters from the President, Provost, and Executive Vice President ceremonies, are 30% post-consumer 9 Michigan State University recycled content. The Commencement 10 Ceremony Lyrics program booklet is 100% post- 11 University Mace consumer recycled content. 12 Academic Attire 13 Keynote Speakers Caps and Gowns 14–16 Keynote Speaker Profles Graduating seniors’ caps and gowns and master’s degrees’ caps and BACCALAUREATE DEGREES gowns are made of post-consumer 18 Honors recycled content; each cap and 19 Order of Ceremonies gown is made of a minimum of 20–21 College of Agriculture and Natural Resources 23 plastic bottles. 22 Residential College in the Arts and Humanities 23–24 College of Arts and Letters Recycle Your Cap and Gown 25–26 The Eli Broad College of Business Once all of your favorite photos are 27–29 College of Communication Arts and Sciences taken on campus, please recycle 30 College of Education your gown at the MSU Union 31–32 College of Engineering Spartan Spirit Shop.
    [Show full text]
  • Annual Report and Accounts 2018 Highlights Contents
    Annual Report and Accounts 2018 Highlights Contents Profit before tax Strategic report and exceptional items Our purpose 1 Our business at a glance 2-3 £761.2m Chairman’s statement 4-5 (2017: £800.3m) Group Chief Executive’s review 6-9 Market review 10-11 Profit before tax Our investment capabilities 12-13 Our strategy for 2018 and beyond 14-15 £649.9m Key performance indicators 16-17 (2017: £760.2m) Our business model 18-19 A strong financial position 20-21 Total dividend per share Business and financial review 22-29 Creating a place people want to work 30-31 114p Our people 32-33 (2017: 113p) Driving high levels of corporate responsibility 34-35 Our impact on society 36-39 Basic earnings per share Key risks and mitigations 40-47 before exceptional items Governance 215.8p Board of Directors and Bruno Schroder 48-50 Group Management Committee and Company Secretary 51-53 (2017: 226.9p) Corporate governance report 54-59 Nominations Committee report 60-61 Basic earnings per share Audit and Risk Committee report 62-67 183.1p Remuneration report 68-90 Directors’ report 91-93 (2017: 215.3p) Statement of Directors’ responsibilities 94 Total equity Financial statements Consolidated financial statements 96-150 £3.6bn Schroders plc financial statements 151-167 Independent auditor’s report 168-175 (2017: £3.5bn) Shareholder information Shareholder information 176 Five-year consolidated financial summary 177 Glossary 178-180 Our Annual General Meeting (AGM) will be held at 11.30am on 2 May 2019 at 1 London Wall Place, London, EC2Y 5AU.
    [Show full text]